EURETINA 2024: Factors predictive of macular oedema development in patients with silicone oil tamponade

News
Article

Additional previous surgeries and the duration of the SO tamponade had little or no impact

A clinician looks at a retinal scan. Image credit: ©Dario Lo Presti – stock.adobe.com

The macular oedema was not responsive to topical treatments that included steroids, anti-inflammatory agents and carbonic anhydrase inhibitors. Image credit: ©Dario Lo Presti – stock.adobe.com

Enrico Bernardi, MD, from the University Hospital of Bern, Bern, Switzerland, and colleagues reported that retinectomy had a significant effect on the development of macular oedema (ME) in patients who received a silicone oil (SO) tamponade.

The investigative team conducted a single-centre study to determine the factors that might predict the development of ME in patients who underwent pars plana vitrectomy and silicone oil (SO) as tamponade.

Their study was an observational, comparative, and retrospective review of patients who received SO tamponade to treat a rhegmatogenous retinal detachment (RRD) or macular hole.

The investigators collected and analysed the patients’ demographic and clinical features that included age, gender, diagnosis, macular status, lens status, previous retinal surgeries, presence of proliferative vitreoretinopathy (PVR), retinectomy, type of SO, duration of tamponade, best-corrected visual acuity, central macular thickness (CMT) and follow-up.

The main outcome measure was the development of ME during and after SO tamponade.

The study included 114 patients (average age, 60 years), most of whom were men (69%). Most of the patients, 85%, had a RRD (85%), about three-quarters of which were macula-off. Most patient had PVR.

The analysis found that ME developed in 54% of eyes. The mean CMT was 443 μm in the presence of ME and 274 μm without ME (p > 0.0001). Following removal of the SO, the CMT decreased in the group with ME to 362 μm; in the group without ME, the CMT was 292 μm (p = 0.019), the authors reported.

The ME was not responsive to topical treatments that included steroids, anti-inflammatory agents and carbonic anhydrase inhibitors.

The study patients had an average follow-up of 104 weeks. Patients who underwent retinectomy had an increased odds of development of ME by about 2.6 times (odds ratio [OR], 2.614). Interestingly, the macula-on status of the RRD markedly reduced the OR (OR, 0.2104), suggesting that it provided a protective effect. The variables analysed that had little or no impact were additional previous surgeries (OR, 1.07) and the duration of the SO tamponade (OR, 0.99).

Dr Bernardi and colleagues concluded, “Our study highlights the significant influence of retinectomy on the development of ME in patients who received a SO tamponade. This correlation was proven to be much more important than the duration of the SO tamponade itself. Treatment strategies should be investigated and refined in this complex context.”

Reference

Bernardi E, Desideri LF, Aissani M, Zinkernagel M, Anguita R. Predictive Factors for Macular Edema Development in Patients with Silicone Oil Tamponade. Presented at the 24th Euretina Congress, Barcelona, Spain, September 19-22. Session: Free Paper Vitreoretinal Surgery
Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.